Systemic lupus erythematosus
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Systemic lupus erythematosus
- Therapeutic area
- Immunology
- systemic lupus erythematosus
- Lupus
- SLE
- SLE - lupus erythematosus, systemic
- disseminated lupus erythematosus
- lupus erythematosus, systemic
- systemic lupus erythematosus
- systemic lupus erythematosus (disease)
- systemic lupus erythematosus susceptibility to
- Severity
- Severe
- Genetic
- Hereditary
- Immunology
- Rheumatology
- MONDO ID
- MONDO:0007915
- Parent condition
- MONDO:0004670
Related records
Broader conditions (12)
- Autoimmune disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Hereditary disorder of connective tissue
- Human disease
- Immune system disorder
- Lupus erythematosus
- Rheumatic disorder
Narrower conditions (12)
- Autosomal systemic lupus erythematosus type 16
- Bullous systemic lupus erythematosus
- Central nervous system lupus
- Neonatal lupus erythematosus
- Pediatric systemic lupus erythematosus
- Systemic lupus erythematosus 17
- Systemic lupus erythematosus 18
- Systemic lupus erythematosus related to C1QA
- Systemic lupus erythematosus related to C1QB
- Systemic lupus erythematosus related to C1QC
- Systemic lupus erythematosus related to C1S
- Systemic lupus erythematosus related to C4A
Trials (1,247)
- " TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus
- (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE
- 2-HOBA in Systemic Lupus Erythematosus
- 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus
- 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
- 3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
- A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
- A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
- A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
- A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
Approved drugs (7)
- Anifrolumab
- Belimumab
- Cortisone acetate
- Dexamethasone
- Dexamethasone sodium phosphate
- Prednisolone
- Prednisone
Drugs in development (155)
- Abatacept Phase 2
- Abetimus sodium Phase 3
- Abrocitinib Phase 2
- Acazicolcept Phase 1
- Acetaminophen Phase 3
- Acetylcysteine Phase 2
- Afimetoran Phase 1
- Aldesleukin Phase 3
- Alnuctamab Phase 1
- AMG-557 Phase 1
- AMG-811 Phase 1
- Amiselimod hydrochloride Phase 1
- APG-2575 Phase 1
- Arsenic trioxide Phase 2
- Artenimol Phase 2
- Aspirin Phase 2
- Atacicept Phase 2
- Atorvastatin Phase 3
- Avizakimab Phase 1
- Azathioprine Phase 3
Other linked drugs (4)
- Budoprutug
- Calcium
- Duloxetine hydrochloride
- Modafinil